Insurance Lawyer in Dubai
At NYK Law Firm, our team of experienced...
North America NGS Automation Market: Transforming Genomic Research and Clinical Diagnostics
Meticulous Research®, a globally recognized market research company, has recently released a report titled, "North America NGS Automation Market by Product {Workstations, Consumables}, Sequencing Type {Whole Genome, Exome, Targeted Genome}, Application {Drug Discovery, Diagnostics, Oncology}, End User {Hospitals, Pharmaceutical, Diagnostic Labs} - Forecast to 2030." This report sheds light on the growing market of Next-Generation Sequencing (NGS) automation in North America, with projections indicating a robust compound annual growth rate (CAGR) of 14% from 2024, pushing the market value to an estimated $776.1 million by 2030.Download Sample Research PDF @ https://www.meticulousresearch.com/download-sample-report/cp_id=5736
Factors Driving the Growth of the NGS Automation Market in North America
Several factors contribute to the rapid expansion of the NGS automation market in North America. One of the most significant drivers is the increasing incidence of cancer across the region. NGS technology plays a crucial role in cancer research and diagnostics, facilitating the identification of genetic mutations and the development of targeted therapies. With cancer becoming more prevalent, the demand for advanced genomic solutions, such as NGS, has risen exponentially.
The surge in demand for NGS automation within laboratories is another key factor propelling the market. Laboratories seek to optimize and streamline workflows, reduce human error, and improve throughput. Automation offers numerous benefits, including higher efficiency, reduced turnaround time, and enhanced reproducibility, making it a vital component in modern genomic research and clinical diagnostics.
Furthermore, the growing investments in pharmaceutical research and development (R&D) and increasing healthcare expenditures across North America are adding momentum to market growth. Pharmaceutical companies are leveraging NGS technology in drug discovery, using automated platforms to accelerate the identification of novel drug targets and develop cutting-edge therapeutic techniques. This growing application of NGS across multiple domains is opening up immense opportunities for market expansion.
Additionally, collaborations between key vendors to develop innovative library preparation protocols for NGS are likely to further drive the adoption of automated platforms. However, despite the promising growth potential, the high costs associated with automation workstations may hinder the market's expansion to some extent, particularly among smaller laboratories with limited budgets.
Key Players in the North America NGS Automation Market
Several major players are actively shaping the North America NGS automation market. Companies like Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Eppendorf AG (Germany), and Hamilton Company (U.S.) are at the forefront of innovation. Other prominent names in the industry include PerkinElmer, Inc. (U.S.), Tecan Group Ltd. (Switzerland), and Hudson Robotics (U.S.). These companies are known for their technological advancements and contributions to developing sophisticated automation solutions for NGS workflows. The competition among these key players is expected to intensify as they strive to capitalize on the growing market opportunities.
Browse In Depth: https://www.meticulousresearch.com/product/north-america-ngs-automation-market-5736
Market Segmentation: Future Outlook
The North America NGS automation market has been segmented into various categories, including product, sequencing type, application, end user, and country. This segmentation allows for a more granular analysis of the market, helping stakeholders understand specific trends and opportunities.
Product Segmentation
In terms of products, the market is divided into two main categories: workstations/robotic platforms and reagents & consumables. Among these, the workstations/robotic platforms segment is expected to hold the largest share of the market in 2024. This can be attributed to the numerous advantages that automation brings to NGS workflows, especially during the library preparation process. Automated workstations enable high throughput, lower per-sample costs, and greater reproducibility compared to manual methods. As the demand for automated solutions grows, particularly in pharmaceutical and biotechnology companies engaged in drug discovery, this segment is likely to dominate the market.
Sequencing Type Segmentation
When it comes to sequencing types, the report identifies whole genome sequencing, whole exome sequencing, and targeted genome sequencing as the primary categories. Whole genome sequencing is projected to account for the largest share of the market in 2024. This segment’s growth can be attributed to the increasing use of NGS in drug discovery and clinical diagnostics. Researchers and healthcare professionals are increasingly utilizing whole genome sequencing to identify genetic mutations, understand disease mechanisms, and develop personalized therapies. This trend is particularly strong in cancer research, where whole genome sequencing aids in the identification of novel drug targets and the development of precision medicine strategies.
Application Segmentation
By application, the North America NGS automation market is divided into drug discovery, clinical diagnostics, and other applications. Clinical diagnostics are further subdivided into categories like reproductive health diagnostics, oncology diagnostics, and infectious disease diagnostics. Among these, drug discovery is expected to account for the largest share of the market in 2024. The growing use of NGS in identifying novel drug targets and developing therapeutic techniques such as gene therapies and oligonucleotide therapies is driving the demand for NGS automation in this sector. Pharmaceutical companies are increasingly adopting NGS technology in their R&D processes to streamline drug discovery and bring new treatments to market more efficiently.
End User Segmentation
The end-user segment of the North America NGS automation market is classified into pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, academic & research institutes, and other end users. In 2024, pharmaceutical and biotechnology companies are expected to dominate the market, holding the largest share. This dominance is attributed to the increasing R&D expenditure in the pharmaceutical industry and the growing demand for advanced technologies in drug discovery. As companies continue to invest in cutting-edge solutions, the demand for NGS automation platforms is expected to rise, enabling faster and more accurate genomic analysis.
Country-Level Insights
Among all the countries studied in the report, the U.S. is expected to lead the North America NGS automation market in 2024. Several factors contribute to the U.S.'s dominant position in the market. Firstly, the country has a strong pharmaceutical and biotechnology sector, with significant investments in R&D. The presence of leading NGS automation platform providers in the U.S. also supports the market's growth.
Additionally, the U.S. government has implemented favorable initiatives to support genomics research, such as grants and funding programs for cancer research. These initiatives have encouraged the adoption of NGS-based research across various applications, including drug discovery and clinical diagnostics. The rising awareness of NGS-based tests among healthcare providers and patients, coupled with the increasing prevalence of cancer, has further fueled the demand for NGS automation in the U.S.
The favorable reimbursement scenario for NGS-based tests in the U.S. has also played a crucial role in driving market growth. As more NGS tests become eligible for reimbursement, healthcare providers are more likely to adopt these technologies, contributing to the expansion of the NGS automation market.
Quick Buy – North America NGS Automation Market – Opportunity Analysis and Industry Forecast (2024-2030), Research Report: https://www.meticulousresearch.com/Checkout/75503538
Conclusion
In summary, the North America NGS automation market is poised for significant growth over the next few years, driven by the increasing demand for advanced genomic technologies in drug discovery, clinical diagnostics, and cancer research. The automation of NGS workflows offers numerous benefits, including higher efficiency, improved accuracy, and reduced costs, making it an attractive option for laboratories, pharmaceutical companies, and research institutions.
With key players continuously innovating and expanding their product offerings, and favorable government initiatives supporting the adoption of NGS technologies, the North America NGS automation market is set to experience robust growth, reaching an estimated value of $776.1 million by 2030.
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Please login to comment on this Post